ATE517179T1 - Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür - Google Patents
Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafürInfo
- Publication number
- ATE517179T1 ATE517179T1 AT02753754T AT02753754T ATE517179T1 AT E517179 T1 ATE517179 T1 AT E517179T1 AT 02753754 T AT02753754 T AT 02753754T AT 02753754 T AT02753754 T AT 02753754T AT E517179 T1 ATE517179 T1 AT E517179T1
- Authority
- AT
- Austria
- Prior art keywords
- cryptovirus
- disclosed
- methods
- nucleic acids
- isolated
- Prior art date
Links
- 241000405758 Betapartitivirus Species 0.000 title abstract 11
- 241001533467 Rubulavirus Species 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 239000002245 particle Substances 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 241000711504 Paramyxoviridae Species 0.000 abstract 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 abstract 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 abstract 1
- 238000010171 animal model Methods 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000012620 biological material Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 230000001787 epileptiform Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000012750 in vivo screening Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 230000001902 propagating effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26725301P | 2001-02-07 | 2001-02-07 | |
| PCT/US2002/004117 WO2002077211A2 (en) | 2001-02-07 | 2002-02-07 | A virus (cryptovirus) within the rubulavirus genus and uses therefor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE517179T1 true ATE517179T1 (de) | 2011-08-15 |
Family
ID=23017976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02753754T ATE517179T1 (de) | 2001-02-07 | 2002-02-07 | Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1373477B1 (enExample) |
| JP (1) | JP4324379B2 (enExample) |
| AT (1) | ATE517179T1 (enExample) |
| AU (2) | AU2002306472C1 (enExample) |
| CA (1) | CA2436208C (enExample) |
| WO (1) | WO2002077211A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| FR2938840B1 (fr) * | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| FR2938841B1 (fr) * | 2008-11-21 | 2010-12-17 | Centre Nat Rech Scient | Proteines mutantes de la proteine f de piv-5 et de piv-2 |
| WO2011150320A2 (en) * | 2010-05-27 | 2011-12-01 | University Of Georgia Research Foundation, Inc. | Activators of innate immunity |
| CN113481185B (zh) * | 2021-08-05 | 2022-12-02 | 云南师范大学 | 一种耐盐β-半乳糖苷酶GalNC2-13及其制备方法和应用 |
| WO2025076466A2 (en) * | 2023-10-06 | 2025-04-10 | Cyanvac Llc | Piv5-based vaccines with modified antigen: methods of making and using the same |
-
2002
- 2002-02-07 WO PCT/US2002/004117 patent/WO2002077211A2/en not_active Ceased
- 2002-02-07 AU AU2002306472A patent/AU2002306472C1/en not_active Ceased
- 2002-02-07 AT AT02753754T patent/ATE517179T1/de not_active IP Right Cessation
- 2002-02-07 CA CA2436208A patent/CA2436208C/en not_active Expired - Fee Related
- 2002-02-07 EP EP02753754A patent/EP1373477B1/en not_active Expired - Lifetime
- 2002-02-07 JP JP2002576654A patent/JP4324379B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-06 AU AU2008202524A patent/AU2008202524A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002306472C1 (en) | 2008-10-30 |
| AU2002306472B2 (en) | 2008-03-06 |
| CA2436208C (en) | 2014-04-15 |
| WO2002077211A3 (en) | 2003-10-16 |
| JP4324379B2 (ja) | 2009-09-02 |
| EP1373477A2 (en) | 2004-01-02 |
| AU2008202524A1 (en) | 2008-06-26 |
| WO2002077211A2 (en) | 2002-10-03 |
| JP2005503766A (ja) | 2005-02-10 |
| CA2436208A1 (en) | 2002-10-03 |
| EP1373477B1 (en) | 2011-07-20 |
| WO2002077211A8 (en) | 2002-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cayrol | IL-33, an alarmin of the IL-1 family involved in allergic and non allergic inflammation: focus on the mechanisms of regulation of its activity | |
| Dyer et al. | The RNase a superfamily: generation of diversity and innate host defense | |
| Luan et al. | NOD-like receptor protein 3 inflammasome-dependent IL-1β accelerated ConA-induced hepatitis | |
| Strutt et al. | Multipronged CD 4+ T‐cell effector and memory responses cooperate to provide potent immunity against respiratory virus | |
| Dobrovolskaia et al. | Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles | |
| US8334101B2 (en) | Intracellular DNA receptor | |
| JP5308161B2 (ja) | 損傷組織の機能的再生促進医薬 | |
| Huang et al. | Enveloped virus labeling via both intrinsic biosynthesis and metabolic incorporation of phospholipids in host cells | |
| RU2546249C2 (ru) | Композиция для усиления экспрессии трансгена в эукариотических клетках и способ увеличения продукции целевого белка, кодируемого трансгеном | |
| Kierstead et al. | gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells | |
| Goel et al. | Serine protease P er a 10 from P eriplaneta americana bias dendritic cells towards type 2 by upregulating CD 86 and low IL‐12 secretions | |
| CN109239334A (zh) | 建立时间分辨荧光免疫层析法检测MxA试剂盒 | |
| Seedhom et al. | Protein translation activity: a new measure of host immune cell activation | |
| TW201927813A (zh) | 用於治療及／或預防異位性皮膚炎之ｉｌ－３１胜肽免疫原及其劑型 | |
| ATE517179T1 (de) | Virus (cryptovirus) innerhalb der gattung rubulavirus und verwendungen dafür | |
| Cheng et al. | Transgenic expression of human C-type lectin protein CLEC18A reduces dengue virus type 2 infectivity in Aedes aegypti | |
| Sebastião et al. | CuMV VLPs containing the RBM from SARS-CoV-2 spike protein drive dendritic cell activation and Th1 polarization | |
| Nishihara et al. | Enhanced cellular uptake of CpG DNA by α-helical antimicrobial peptide Kn2-7: Effects on macrophage responsiveness to CpG DNA | |
| Boulaire et al. | Gene expression profiling to define host response to baculoviral transduction in the brain | |
| Pagneux et al. | Neutralization of SARS-CoV-2 and intranasal protection of mice with a nanoCLAMP antibody mimetic | |
| Masalova et al. | Mesenchymal stem cells can both enhance and inhibit the cellular response to DNA immunization by genes of nonstructural proteins of the hepatitis C Virus | |
| Zhang et al. | PLZF-expressing CD4+ T cells promote tissue-resident memory T cells in breaking immune tolerance in allergic asthma via IL-15/IL-15Rα signaling | |
| Chen et al. | An Intein-Spliced Nipah G Protein Ferritin Nanoparticle Vaccine Provides Complete Protection against Lethal Nipah Virus Challenge | |
| KR102091748B1 (ko) | 수지상세포의 이동능을 증가시키는 방법 및 이의 용도 | |
| DE60138952D1 (de) | 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |